

Murtuza Bharmal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1287894/publications.pdf>

Version: 2024-02-01

42
papers

1,688
citations

471509

17
h-index

289244

40
g-index

44
all docs

44
docs citations

44
times ranked

2535
citing authors

#	ARTICLE	IF	CITATIONS
1	Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. <i>European Journal of Cancer</i> , 2017, 71, 53-69.	2.8	307
2	Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications. <i>Health and Quality of Life Outcomes</i> , 2009, 7, 36.	2.4	200
3	Prevalence and disease burden of primary restless legs syndrome: Results of a general population survey in the United States. <i>Movement Disorders</i> , 2011, 26, 114-120.	3.9	187
4	National Trends in Staphylococcus aureus Infection Rates: Impact on Economic Burden and Mortality over a 6-Year Period (1998-2003). <i>Clinical Infectious Diseases</i> , 2007, 45, 1132-1140.	5.8	166
5	Comparing the EQ-5D and the SF-6D Descriptive Systems to Assess Their Ceiling Effects in the US General Population. <i>Value in Health</i> , 2006, 9, 262-271.	0.3	156
6	Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma. <i>Future Oncology</i> , 2017, 13, 1263-1279.	2.4	113
7	Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA. <i>Future Oncology</i> , 2017, 13, 1699-1710.	2.4	98
8	Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe. <i>Oncotarget</i> , 2017, 8, 79731-79741.	1.8	77
9	Prevalence and correlates of potentially inappropriate prescribing among ambulatory older patients in the year 2001: Comparison of three explicit criteria. <i>Clinical Therapeutics</i> , 2005, 27, 88-99.	2.5	45
10	Health Insurance Coverage and Health-Related Quality of Life: Analysis of 2000 Medical Expenditure Panel Survey Data. <i>Journal of Health Care for the Poor and Underserved</i> , 2005, 16, 643-654.	0.8	25
11	Survey of pharmacist collaborative drug therapy management in hospitals. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 2489-2499.	1.0	23
12	Budget Impact Analysis of Rapid Screening for <i>Staphylococcus aureus</i> Colonization Among Patients Undergoing Elective Surgery in US Hospitals. <i>Infection Control and Hospital Epidemiology</i> , 2008, 29, 16-24.	1.8	23
13	Nonprogression with avelumab treatment associated with gains in quality of life in metastatic Merkel cell carcinoma. <i>Future Oncology</i> , 2018, 14, 255-266.	2.4	22
14	Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 609-618.	4.2	21
15	Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma. <i>Pharmacoeconomics - Open</i> , 2019, 3, 377-390.	1.8	20
16	Incremental Dementia-Related Expenditures in a Medicaid Population. <i>American Journal of Geriatric Psychiatry</i> , 2012, 20, 73-83.	1.2	18
17	Using Response Evaluation Criteria in Solid Tumors in real-world evidence cancer research. <i>Future Oncology</i> , 2018, 14, 2841-2848.	2.4	17
18	Patient preferences for adherence enhancing tools. <i>Journal of Communication in Healthcare</i> , 2010, 3, 266-278.	1.5	14

#	ARTICLE	IF	CITATIONS
19	Validation of a Women's Sexual Interest Diagnostic Interview's Short Form (WSID-SF) and a Daily Log of Sexual Activities (DLSA) in Postmenopausal Women with Hypoactive Sexual Desire Disorder. <i>Journal of Sexual Medicine</i> , 2010, 7, 917-927.	0.6	14
20	Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 247.	2.4	14
21	Validation of the post sleep questionnaire for assessing subjects with restless legs syndrome: results from two double-blind, multicenter, placebo-controlled clinical trials. <i>BMC Neurology</i> , 2011, 11, 48.	1.8	13
22	How to address the challenges of evaluating treatment benefits-risks in rare diseases? A convergent mixed methods approach applied within a Merkel cell carcinoma phase 2 clinical trial. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 95.	2.7	13
23	Resource utilisation, charges and mortality following hospital inpatient admission for congestive heart failure among the elderly in the US. <i>Journal of Medical Economics</i> , 2008, 11, 397-414.	2.1	11
24	Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial. <i>Patient</i> , 2020, 13, 457-467.	2.7	11
25	Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection. <i>BMC Medical Research Methodology</i> , 2020, 20, 103.	3.1	10
26	Development and validation of a Subjective Post Sleep Diary (SPSD) to assess sleep status in subjects with Restless Legs Syndrome. <i>Sleep Medicine</i> , 2011, 12, 704-710.	1.6	9
27	Living with Merkel Cell Carcinoma (MCC): Development of a Conceptual Model of MCC Based on Patient Experiences. <i>Patient</i> , 2018, 11, 439-449.	2.7	9
28	Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab. <i>Advances in Therapy</i> , 2019, 36, 2327-2341.	2.9	8
29	Comparative effectiveness of avelumab versus chemotherapy in Merkel cell carcinoma: innovative use of patient insights. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 881-890.	1.4	6
30	Update on the psychometric properties and minimal important difference (MID) thresholds of the FACT-M questionnaire for use in treatment-naïve and previously treated patients with metastatic Merkel cell carcinoma. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 145.	2.4	6
31	Systematic literature review of current treatments for stage III Merkel cell carcinoma. <i>Future Oncology</i> , 2021, 17, 4813-4822.	2.4	5
32	&#x26;Treatment Sequencing Patterns in Patients with Metastatic Urothelial Cancer Treated in the Community Practice Setting in the United States: SPEAR-Bladder (Study informing treatment Pathway) <i>Journal of Clinical Oncology</i> , 2021, 39, 645-656.	1.9	5
33	Treatment patterns, comorbidities, healthcare resource use, and associated costs by line of chemotherapy and level of comorbidity in patients with newly-diagnosed Merkel cell carcinoma in the United States. <i>Journal of Medical Economics</i> , 2018, 21, 1159-1171.	2.1	4
34	<p>Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 349-359.	1.9	4
35	What is the Impact of the Analysis Method Used for Health State Utility Values on QALYs in Oncology? A Simulation Study Comparing Progression-Based and Time-to-Death Approaches. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 389-401.	2.1	3
36	Management of Patients With Advanced Urothelial Carcinoma in an Evolving Treatment Landscape: A Qualitative Study of Provider Perspectives of First-Line Therapies. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 114-122.	1.9	3

#	ARTICLE	IF	CITATIONS
37	Psychometric Properties of EQ-5D-5L Scoring Algorithms for the United Kingdom in Metastatic Merkel Cell Carcinoma. Value in Health, 2019, 22, 1170-1177.	0.3	2
38	<p>Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives</p>. ClinicoEconomics and Outcomes Research, 2019, Volume 11, 659-672.	1.9	2
39	Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab. Future Oncology, 2020, 16, 2089-2099.	2.4	2
40	How Assessment-Schedule Matching Limits Bias When Comparing Progression-Free Survival in Single-Arm Studies: An Application in Second-Line Urothelial Carcinoma Treatments. Value in Health, 2021, 24, 1137-1144.	0.3	2
41	Development, Validation, and Application of a Scale to Measure the Impact of the Internet on Market Structure and Competition in the Retail Pharmacy Market. Journal of Pharmaceutical Marketing and Management, 2003, 16, 81-99.	0.1	0
42	Impact of Internet Use on Business Functions in Independent Community Pharmacies. Journal of the American Pharmacists Association: JAPhA, 2003, 43, 720-724.	1.5	0